Eisai R&d Management Co., Ltd.

Shelby Ellery

Dominic J Reynolds

Andrew Cook

Sudeep Prajapati

James Palacino

Xiang Liu

Thiwanka Samarakoon

Megan Sheehan

Nathan Elliott Fishkin

Ping Zhu

Peter G Smith

Silvia Buonamici

Lihua Yu

Ermira Pazolli

Michael W Seiler

Yonghong Xiao

Zhenhua Wu

Nicholas Calandra

Jason T Lowe

Shouyong Peng

John JianShi Wang

Guo Zhu Zheng

Atsushi Endo

Ming-Hong Hao

Yoshihiko Kotake

Gregg F Keaney

Kazunobu Kira

Marta Nevalainen

Parcharee Tivitmahaisoon

Cheng Zhong

Norio Murai

Baudouin Gerard

Satoshi Nagao

Masayuki Miyano

Kenzo Arai

Nicholas C Gearhart

Regina Mikie Kanada Sonobe

Lisa A Marcaurelle

Ryan Brawn

Morgan Welzel O'shea

Tuoping Luo

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Splicing modulator antibody-drug conjugates and methods of use

The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Certain pladienolide compounds and methods of use

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Certain aryl pladienolide compounds and methods of use

Growing community of inventors

Boston, MA, United States of America

Shelby Ellery